Stephanie Delgaudioriemann, MD
Neurology · Woodstock, GANPI 1306819743
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,774 of the $167,108 with a category attached, or 75.3%. 60 manufacturers reported payments, led by AbbVie at 57.8% of the total. Reporting peaked in 2021 at $57,162 and has fallen 95.5% since, to $2,576 in 2025. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,326 payments — averaging $126.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$97K
- Teva Pharmaceuticals USA, Inc.$38K
- Lilly USA, LLC$5K
- Lundbeck LLC$3K
- Biogen$2K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $20K from 54 others
What the payments were for
- Consulting fees$9,7636%
- Speaking & faculty fees$125,77475%
- Travel & lodging$5,3033%
- Food & beverage$26,06616%
- Education$2020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$87,879
- AJOVY$36,014
- QULIPTA$9,675
- NORTHERA$2,413
- VNS - Sentiva$1,716
- OXTELLAR XR$963
- Proclaim Family of SCS IPGs$840
- ZEPOSIA$567
- Vumerity$245
- Epidiolex$139
- Neuromodulation Dspsbls and Accs$125
- TECFIDERA$121
- ULTOMIRIS$100
How this compares
$167,108 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $366,588 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $151,823 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $70,985 |
| BotoxOnabotulinumtoxina | 50 | $61,775 |
| RytaryCarbidopa/Levodopa | 33 | $40,009 |
| BriviactBrivaracetam | 11 | $29,150 |
| VimpatLacosamide | 25 | $28,504 |
| TopamaxTopiramate | 11 | $27,414 |
| Glatiramer Acetate | 11 | $21,450 |
| OxycontinOxycodone Hcl | 12 | $17,663 |
| OnfiClobazam | 11 | $11,439 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,248 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 192 | $7,636 |
| Gabapentin | 104 | $4,742 |
| Depakote ErDivalproex Sodium | 22 | $4,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $37,640 | $366,58824 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $260 | $151,82314 claims |
| Grifols USA, LLCGamunex-C | $56 | $70,98512 claims |
| AbbVieBotox | $96,554 | $61,77550 claims |
| UCB, Inc.Briviact, Vimpat | $1,757 | $57,65436 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $343 | $42,11059 claims |
| Lundbeck LLCOnfi | $3,395 | $11,43911 claims |
| Upsher-smith Laboratories LLCTopiramate | $265 | $2,70216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Woodstock
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
- Dinesh RajuLawrenceville$414K
- Victor RosenfeldSavannah$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.